OBJECTIVE: To determine the effect of artesunate (AT) on the disposition kinetics of sulfadoxine/pyrimethamine (SP) in humans. METHODS: In a randomized cross-over study, 16 healthy volunteers were given a dose of three SP tablets containing 500 mg of sulfadoxine (SDX) and 25 mg of pyrimethamine (PYR) (=SP group), while the second arm received three SP tablets + two AT tablets of 200 mg in total followed by 100 mg AT for the next 4 days (SP+AT group). Blood samples (100 microl) were collected by means of a finger prick and dried on filter paper. The blood spots were wrapped in polythene folders and stored at room temperature until analysis. The samples were assayed using high-performance liquid chromatographic methods. RESULTS: The peak concentration C(max)), time required to attain peak concentration (T(max)), half-life (t ((1/2))) and area under the plasma concentration-time curve (AUC) were determined. The C(max) of SDX were 92.9 and 98.9 microg/ml for the SP and SP+AT arms, respectively; for PYR, these were 0.86 and 0.79 microg/ml, respectively. The T(max) of SDX were 10 and 8 h for the SP and SP+AT arms, respectively; for PYR, these were 4.0 and 3.0 h, respectively. The AUC(0-288) of SDX were 15,840 and 18,876 microg/ml h for the SP and SP+AT arms, respectively; for PYR, they were 124 and 112 microg/ml h, respectively. The t ((1/2)) of values for SDX were 165 and 180 h for the SP and SP+AT arms, respectively; for PYR, these were 158 and 177 h, respectively. There was no statistically significant difference between the C(max), T(max), AUC(0-288) and t ((1/2)) between the two arms (p > 0.05). CONCLUSION: Taking AT concomitantly with SP does not have any impact in the disposition of SP.
RCT Entities:
OBJECTIVE: To determine the effect of artesunate (AT) on the disposition kinetics of sulfadoxine/pyrimethamine (SP) in humans. METHODS: In a randomized cross-over study, 16 healthy volunteers were given a dose of three SP tablets containing 500 mg of sulfadoxine (SDX) and 25 mg of pyrimethamine (PYR) (=SP group), while the second arm received three SP tablets + two AT tablets of 200 mg in total followed by 100 mg AT for the next 4 days (SP+AT group). Blood samples (100 microl) were collected by means of a finger prick and dried on filter paper. The blood spots were wrapped in polythene folders and stored at room temperature until analysis. The samples were assayed using high-performance liquid chromatographic methods. RESULTS: The peak concentration C(max)), time required to attain peak concentration (T(max)), half-life (t ((1/2))) and area under the plasma concentration-time curve (AUC) were determined. The C(max) of SDX were 92.9 and 98.9 microg/ml for the SP and SP+AT arms, respectively; for PYR, these were 0.86 and 0.79 microg/ml, respectively. The T(max) of SDX were 10 and 8 h for the SP and SP+AT arms, respectively; for PYR, these were 4.0 and 3.0 h, respectively. The AUC(0-288) of SDX were 15,840 and 18,876 microg/ml h for the SP and SP+AT arms, respectively; for PYR, they were 124 and 112 microg/ml h, respectively. The t ((1/2)) of values for SDX were 165 and 180 h for the SP and SP+AT arms, respectively; for PYR, these were 158 and 177 h, respectively. There was no statistically significant difference between the C(max), T(max), AUC(0-288) and t ((1/2)) between the two arms (p > 0.05). CONCLUSION: Taking AT concomitantly with SP does not have any impact in the disposition of SP.
Authors: E Ribera; L Pou; R M Lopez; M Crespo; V Falco; I Ocaña; I Ruiz; A Pahissa Journal: J Acquir Immune Defic Syndr Date: 2001-12-15 Impact factor: 3.731
Authors: L von Seidlein; P Milligan; M Pinder; K Bojang; C Anyalebechi; R Gosling; R Coleman; J I Ude; A Sadiq; M Duraisingh; D Warhurst; A Alloueche; G Targett; K McAdam; B Greenwood; G Walraven; P Olliaro; T Doherty Journal: Lancet Date: 2000-01-29 Impact factor: 79.321
Authors: Sakina B Elamin; Elfatih M Malik; Tarig Abdelgadir; Ammar H Khamiss; Mamoun M Mohammed; Elderderi S Ahmed; Ishag Adam Journal: Malar J Date: 2005-09-14 Impact factor: 2.979
Authors: Ishag Adam; Mamoun Magzoub; Maha E Osman; Insaf F Khalil; Michael Alifrangis; Khalid A Elmardi Journal: Ann Clin Microbiol Antimicrob Date: 2006-08-26 Impact factor: 3.944
Authors: Mamadou M Tekete; Sékou Toure; Alfia Fredericks; Abdoul H Beavogui; Cheick P O Sangare; Alicia Evans; Peter Smith; Hamma Maiga; Zoumana I Traore; Ogobara K Doumbo; Karen I Barnes; Abdoulaye A Djimde Journal: Malar J Date: 2011-09-21 Impact factor: 2.979